

## **LISTING OF THE CLAIMS**

Claims 1 – 114: (Canceled)

Claim 115: (Previously presented) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:19; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:9,

wherein the antibody is capable of binding human CTLA-4.

Claim 116: (Previously presented) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:17; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:7,

wherein the antibody is capable of binding human CTLA4.

Claim 117: (Previously presented) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:23; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:13,

wherein the antibody is capable of binding human CTLA4.

Claim 118: (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:27, 32 and 37; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:24, 29 and 35.

Claim 119: (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:27, 33 and 37; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:25, 30 and 35.

Claim 120: (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:28, 34 and 38; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:26, 31 and 36.

Claim 121: (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region of a human  $V_H$  3-30.3 gene; and
- (b) a light chain variable region of a human  $V_K$  A-27 gene.

Claim 122: (Previously presented) An antibody according to claim 121, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^8 M^{-1}$  or greater.

Claim 123: (Previously presented) An antibody according to claim 121, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^9 M^{-1}$  or greater.

Claim 124: (Previously presented) An antibody according to claim 121, wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

Claims 125-126: (Canceled)

Claim 127: (Previously presented) An antibody according to claim 121, wherein the antibody is a therapeutically-effective antibody that does not cross react with non-lymphoid tissue.

Claims 128-129: (Canceled)

Claim 130 (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region of a human  $V_H$  3-33 gene; and
- (b) a light chain variable region of a human  $V_K$  L-15 gene.

Claim 131 (Previously presented) An antibody according to claim 130, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^8 M^{-1}$  or greater.

Claim 132 (Currently amended) An antibody according to claim 130, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^9 M^{-1}$  or greater.

Claim 133 (Previously presented) An antibody according to claim 130, wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

Claims 134-150: (Canceled)

Claim 151: (Currently amended) A pharmaceutical composition comprising an ~~An~~ isolated therapeutically-effective human monoclonal antibody or antigen-binding portion thereof that specifically binds to human CTLA-4, wherein the antibody or antigen-binding portion thereof has a binding affinity that is about  $10^8 M^{-1}$  or greater affinity and does not cross-react with non-lymphoid tissue.

Claim 152: (Currently amended) A pharmaceutical composition comprising a therapeutically-effective antibody according to claim 151 wherein the antibody comprises ~~comprising~~:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:17; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:7.